These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16971117)

  • 61. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
    Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
    ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nonsteroidal progesterone receptor ligands (I): synthesis and SAR of new tetrahydronaphthofuranone derivatives.
    Shinei R; Kurihara K; Tanabe K; Tabata Y; Kurata Y; Hoshiko S; Okonogi T
    Bioorg Med Chem; 2006 Jul; 14(14):4850-61. PubMed ID: 16580213
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel methylene-linked heterocyclic EP1 receptor antagonists.
    Hall A; Bit RA; Brown SH; Chowdhury A; Giblin GM; Hurst DN; Kilford IR; Lewell X; Naylor A; Scoccitti T
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1592-7. PubMed ID: 18262416
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
    Zhang X; Tellew JE; Luo Z; Moorjani M; Lin E; Lanier MC; Chen Y; Williams JP; Saunders J; Lechner SM; Markison S; Joswig T; Petroski R; Piercey J; Kargo W; Malany S; Santos M; Gross RS; Wen J; Jalali K; O'Brien Z; Stotz CE; Crespo MI; Díaz JL; Slee DH
    J Med Chem; 2008 Nov; 51(22):7099-110. PubMed ID: 18947224
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
    Drizin I; Gregg RJ; Scanio MJ; Shi L; Gross MF; Atkinson RN; Thomas JB; Johnson MS; Carroll WA; Marron BE; Chapman ML; Liu D; Krambis MJ; Shieh CC; Zhang X; Hernandez G; Gauvin DM; Mikusa JP; Zhu CZ; Joshi S; Honore P; Marsh KC; Roeloffs R; Werness S; Krafte DS; Jarvis MF; Faltynek CR; Kort ME
    Bioorg Med Chem; 2008 Jun; 16(12):6379-86. PubMed ID: 18501613
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synthesis and antibacterial activity of new 7-piperazinyl-quinolones containing a functionalized 2-(furan-3-yl)ethyl moiety.
    Foroumadi A; Mohammadhosseini N; Emami S; Letafat B; Faramarzi MA; Samadi N; Shafiee A
    Arch Pharm (Weinheim); 2007 Jan; 340(1):47-52. PubMed ID: 17206610
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors.
    Manera C; Betti L; Cavallini T; Giannaccini G; Martinelli A; Ortore G; Saccomanni G; Trincavelli L; Tuccinardi T; Ferrarini PL
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4604-10. PubMed ID: 16099648
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification and optimization of novel 1,3,4-oxadiazole EP1 receptor antagonists.
    Hall A; Brown SH; Chowdhury A; Giblin GM; Gibson M; Healy MP; Livermore DG; Wilson RJ; Naylor A; Rawlings DA; Roman S; Ward E; Willay C
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4450-5. PubMed ID: 17574410
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists.
    Lim CJ; Kim NH; Park HJ; Lee BH; Oh KS; Yi KY
    Bioorg Med Chem Lett; 2019 Feb; 29(4):577-580. PubMed ID: 30611618
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthesis and pharmacological characterization of chiral pyrrolidinylfuran derivatives: the discovery of new functionally selective muscarinic agonists.
    Scapecchi S; Nesi M; Matucci R; Bellucci C; Buccioni M; Dei S; Guandalini L; Manetti D; Martini E; Marucci G; Romanelli MN; Teodori E; Cirilli R
    J Med Chem; 2008 Jul; 51(13):3905-12. PubMed ID: 18543900
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A2A adenosine-receptor-mediated facilitation of noradrenaline release in rat tail artery involves protein kinase C activation and betagamma subunits formed after alpha2-adrenoceptor activation.
    Fresco P; Oliveira JM; Kunc F; Soares AS; Rocha-Pereira C; Gonçalves J; Diniz C
    Neurochem Int; 2007 Jul; 51(1):47-56. PubMed ID: 17493708
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of 7-(Prolinol-N-yl)-2-phenylamino-thiazolo[5,4-d]pyrimidines as Novel Non-Nucleoside Partial Agonists for the A2A Adenosine Receptor: Prediction from Molecular Modeling.
    Bharate SB; Singh B; Kachler S; Oliveira A; Kumar V; Bharate SS; Vishwakarma RA; Klotz KN; Gutiérrez de Terán H
    J Med Chem; 2016 Jun; 59(12):5922-8. PubMed ID: 27227326
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dihydrofuro[3,4-c]pyridinones as inhibitors of the cytolytic effects of the pore-forming glycoprotein perforin.
    Lena G; Trapani JA; Sutton VR; Ciccone A; Browne KA; Smyth MJ; Denny WA; Spicer JA
    J Med Chem; 2008 Dec; 51(23):7614-24. PubMed ID: 19007200
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.
    Watson RJ; Allen DR; Birch HL; Chapman GA; Hannah DR; Knight RL; Meissner JW; Owen DA; Thomas EJ
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6806-10. PubMed ID: 17964154
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.
    Moorjani M; Zhang X; Chen Y; Lin E; Rueter JK; Gross RS; Lanier MC; Tellew JE; Williams JP; Lechner SM; Malany S; Santos M; Ekhlassi P; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Saunders J; Slee DH
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1269-73. PubMed ID: 18249540
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives.
    Lu SF; Chen B; Davey D; Dunning L; Jaroch S; May K; Onuffer J; Phillips G; Subramanyam B; Tseng JL; Wei RG; Wei M; Ye B
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1883-7. PubMed ID: 17314043
    [TBL] [Abstract][Full Text] [Related]  

  • 78. 4-benzyl-3-phenyl-5H-furan-2-one, a vasodilator isolated from Malbranchea filamentosa IFM 41300.
    Hosoe T; Iizuka T; Komai S; Wakana D; Itabashi T; Nozawa K; Fukushima K; Kawai K
    Phytochemistry; 2005 Dec; 66(23):2776-9. PubMed ID: 16213536
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A.
    Chenna BC; Shinkre BA; King JR; Lucius AL; Narayana SV; Velu SE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):380-5. PubMed ID: 18023345
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia.
    Melani A; Cipriani S; Vannucchi MG; Nosi D; Donati C; Bruni P; Giovannini MG; Pedata F
    Brain; 2009 Jun; 132(Pt 6):1480-95. PubMed ID: 19359287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.